Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.45 |
| ▸ | CCNK | O75909 | 6/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.45 |
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CDK9 | P50750 | 6/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 5/20 | 0.40 |
| ▸ | CCNH | P51946 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | BLK | P51451 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526221 | 1.00 | KMT2A (0.48) | KMT2ACCNT1CCNKCCNE1CDK2 | |
| SCHEMBL17196849 | 0.86 | KMT2A (0.50) | KMT2ACCNT1CCNKCCNE1CDK2 | |
| SCHEMBL586310 | 0.84 | KMT2A (0.60) | KMT2AAXL | |
| SCHEMBL1976634 | 0.84 | KMT2A (0.65) | KMT2AAXL | |
| SCHEMBL29860203 | 0.84 | KMT2A (0.65) | KMT2AAXL | |
| SCHEMBL17797536 | 0.84 | KMT2A (0.70) | KMT2ACCNT1CCNKCCNE1CDK2 | |
| SCHEMBL17797539 | 0.84 | KMT2A (0.70) | KMT2ACCNT1CCNKCCNE1CDK2 | |
| SCHEMBL24799800 | 0.83 | KMT2A (0.68) | KMT2AAXL | |
| SCHEMBL2302601 | 0.83 | KMT2A (0.68) | KMT2AAXL | |
| SCHEMBL2305520 | 0.83 | KMT2A (0.68) | KMT2AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | KMT2A 523/4885CCNT1 2794/4885CCNK 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.